Our Leadership

NewAmsterdam Pharma has assembled a group of industry experts with proven track
records to support the development of treatments for cardiovascular disease (CVD) and
other lipid-related conditions.

Each individual’s clinical, regulatory, business, or commercial experience contributes to
our unparalleled leadership team. Team members have served in senior positions at
several cardiovascular-focused companies, including Corvidia Therapeutics, Omthera,
AstraZeneca, Sanofi, Amgen, Merck, and BioHaven.

NewAmsterdam Pharma is led by physicians—and two of the foremost experts in
lipidology and CVD—Dr. Michael Davidson and Professor John Kastelein. Our
management team has played critical roles in the development and commercialization of
therapies such as Zocor, Crestor, Brilinta, Zetia, Vytorin, Nurtec ODT, Farxiga, Pradaxa,
and other blockbusters.